Tuesday , October 4 2022

[바이오 유망기업]⑨ Utrex maintains the world leader in the next-generation immune carcinogen



[ad_1]

[이데일리 이미나 기자]
[이데일리 김지섭 기자] "Innovative immunotherapy-based technologies will develop cell therapy and antibody therapies and become a global leader in immunosuppressive drugs through rapid commercialization."

Kwon Byung-se, the company's spokeswoman, met with reporters at the Plaza Hotel in Jung-gu, Seoul on the 16th.

Utrex is a biotechnology company that develops drugs for incompatible diseases such as immunotherapy using an "immune system" that protects viruses and toxins in the human body. The Utrex mission statement also showed the intention to develop new immunotherapeutic drugs such as "EU" (new), "TI" (immunotherapy) and "LEX" (method).

The immunotoxic drug treats cancer cells with a normal immune system or enhances the attenuated immune system in a variety of ways to remove cancer cells. Compared to conventional cancer drugs or targeted cancer drugs that affect certain cancer cells, they are less resistant to drugs and safe from side effects such as leucopenia and hair loss. According to GBI Research, the market for immunotherapeutic drugs is expected to grow at an average annual rate of 23.9% from 18 trillion profits in 2015 to 86 trillion profits in 2022.

◇ Immunology Research & amp; Hanwoo & amp; … Original technology for immunotherapy was acquired

Kwon Byung-seh, who founded Utilities in February 2015, is an authority in the field of immunology, working on selling kangwoo products. He was Professor of Chemistry and Bioscience at the University of Ulsan and Head of the Immunocytochemistry Division of the National Cancer Center at Yale University. "The study of immunology for the last 40 years has led to the development of differentiated immunotherapy".

Specifically, it was first observed in 1989 when it discovered the receptor "4-1BB", which stimulates "T cells" associated with the immunomodulatory drug of the antibody. T cells, an immune cell, attack and destroy cancer cells. 4-1BB can selectively activate or reduce immune function to activate T cells. Utrex uses this to separate and cultivate T cells from the blood of cancer patients and then to inject them into the patient's body.

(EBViNT Cell), which treats lymphoma, laryngeal cancer, stomach cancer, etc. It is a monophasic tumor of glioblastoma / malignant tumor that has lung cancer and breast cancer ½ phase. WTiNT Cell, which treats glioma, etc., is in phase one. "Aptity Cell will complete the second phase of clinical trials by 2020," he said. "Its purpose is to license the Food and Drug Administration (FDA) in 2022 through the definition of innovative medicines."

Additionally, a "T-cell expressing a chimeric antigen receptor" (CAR-T) that enhances the anticancer effect by introducing a gene that successfully discovers and destroys the cancer cells in T cells (CAR). The existing CAR- T has caused side effects such as cytokine syndrome that affects normal cells indiscriminately and causes hypotension and acute renal damage. However, CAR-T treatments of utilities reduced the adverse effects only attacking malignant cells, targeting "HDL-DR", an antigen expressed when normal cells are transformed into malignant cells. By standardizing the production process and standardizing the product, the cost of the drug, which has reached several hundred million millions of victories, has fallen sharply. Other drugs such as EU101 and EU102, which are active in the treatment of cancer cells by activating the immune response of T cells, are growing.

These new developmental drugs are also looking for active technology exports. Mr Kwon said: "There are many technologies we have now, but it is impossible to develop them all." He said: "We will increase clinical costs through technology exports and we will work with global pharmaceutical companies to build success stories."

◇ New drug development in the US, such as the bridge … Global ambition "Global Big Pharma"

Kwon's key priority is to build a stronghold in the US and Europe to develop new drugs. In September, we signed a Memorandum of Understanding with the American JGBLI (JG Business Link International) and ABB Anti-Cell for successful US entry. JGBLI will support research and development centers in the United States and consultation with the Maryland College of Pharmacy for the approval of cancer drugs. "This is the first step in clinical trials for T cell therapy in the United States," said Kwon. "We will continue to make efforts to obtain immunocompromised medicines, starting with App VientiCell."

The KOSDAQ list for clinical funding is also ahead. On December 15, the Korean Stock Exchange's preliminary check passed and confirmed the estimated $ 27.6 billion to 36.4 billion profits. "From 2022 to the year of launches of products and technology exports etc. Growth by 2013, global anti-poverty competition," We will achieve our vision ".

[ad_2]
Source link